预约演示
更新于：2026-10-21
Amezalpat
更新于：2026-10-21
概要
基本信息
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床1/2期 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C34H41N3O4 |
InChIKeyKUPVZYDOHAPPNF-UHFFFAOYSA-N |
CAS号1616372-41-8 |
关联
3
项与 Amezalpat 相关的临床试验NCT06680258
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy
The goal of this clinical trial is to determine if TPST-1120 in combination with atezolizumab and bevacizumab helps patients to live longer compared to atezolizumab and bevacizumab alone (the standard of care treatment) in adult patients with hepatocellular carcinoma that cannot be removed by surgery or has spread outside of the liver (called metastatic). The trial also will study the safety and side effects of the drug combination compared to the standard of care treatment. Other questions the trial aims to answer include:
1. Does TPST-1120 in combination with atezolizumab and bevacizumab improve the time that patients are alive and cancer is not growing (progression free survival) compared to atezolizumab and bevacizumab
2. Does TPST-1120 in combination with atezolizumab and bevacizumab improve the shrinking of cancer (the overall response rate) compared to atezolizumab and bevacizumab
Trial participants will be randomly assigned to take one of the following:
1. TPST-1120 3 tablets (600 mg) by mouth twice a day every day along with atezolizumab 1200 mg intravenously every 3 weeks and bevacizumab 15 mg/kg intravenously every 3 weeks
2. Placebo (look-alike that does not contain study drug) 3 tablets by mouth twice a day every day along with atezolizumab 1200 mg intravenously once every 3 weeks and bevacizumab 15 mg/kg intravenously once every 3 weeks
Trial participants will receive routine and trial-specific cancer care from their study doctor including
* visits to the clinic every 3 weeks for physical examination, labs and questions about health and symptoms
* measurement of their cancer by CT scan every 9 weeks.
Trial participants can stop study treatment at any time they choose and for any reason. They also can continue to receive study treatment for as long as the treatment is controlling cancer growth and they are tolerating the drug effects.
1. Does TPST-1120 in combination with atezolizumab and bevacizumab improve the time that patients are alive and cancer is not growing (progression free survival) compared to atezolizumab and bevacizumab
2. Does TPST-1120 in combination with atezolizumab and bevacizumab improve the shrinking of cancer (the overall response rate) compared to atezolizumab and bevacizumab
Trial participants will be randomly assigned to take one of the following:
1. TPST-1120 3 tablets (600 mg) by mouth twice a day every day along with atezolizumab 1200 mg intravenously every 3 weeks and bevacizumab 15 mg/kg intravenously every 3 weeks
2. Placebo (look-alike that does not contain study drug) 3 tablets by mouth twice a day every day along with atezolizumab 1200 mg intravenously once every 3 weeks and bevacizumab 15 mg/kg intravenously once every 3 weeks
Trial participants will receive routine and trial-specific cancer care from their study doctor including
* visits to the clinic every 3 weeks for physical examination, labs and questions about health and symptoms
* measurement of their cancer by CT scan every 9 weeks.
Trial participants can stop study treatment at any time they choose and for any reason. They also can continue to receive study treatment for as long as the treatment is controlling cancer growth and they are tolerating the drug effects.
开始日期2025-12-01 |
申办/合作机构 |
NCT04524871
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
开始日期2020-11-01 |
申办/合作机构 |
NCT03829436
A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.
开始日期2019-03-20 |
申办/合作机构 |
100 项与 Amezalpat 相关的临床结果
登录后查看更多信息
100 项与 Amezalpat 相关的转化医学
登录后查看更多信息
100 项与 Amezalpat 相关的专利（医药）
登录后查看更多信息
2
项与 Amezalpat 相关的文献（医药）2025-08-01·BIOORGANIC CHEMISTRY
Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment
Review
作者: Ramaa, C S ; Patil, Vijay M ; Lavecchia, Antonio ; Misal, Snehal
Cancer remains one of the leading causes of mortality worldwide, driving the need for novel therapeutic strategies. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors that regulate lipid metabolism, inflammation, and tumor progression. While PPAR agonists have been widely explored for their anticancer potential, recent evidence highlights PPAR antagonists as promising therapeutic candidates. These antagonists selectively modulate oncogenic pathways by disrupting metabolic and signaling networks that support tumor growth, survival, and metastasis. PPARα antagonists, such as N-(2-bromophenyl)-2-[[(3-chlorophenyl)amino]thioxomethyl]acetamide (GW6471) and TPST-1120, impair tumor metabolism and angiogenesis, reducing cancer progression. Their combination with immunotherapy has shown enhanced antitumor effects in preclinical models. PPARβ/δ antagonists, including 4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]benzoic acid (GSK0660) and methyl 3-(N-(4-(hexylamino)-2-methoxyphenyl)sulfamoyl)thiophene-2-carboxylate (ST247), suppress β-catenin-driven oncogenic transcription, modulating cell proliferation and invasion. PPARγ antagonists, such as 2-Chloro-5-nitro-N-phenylbenzamide (T0070907) and 2-Chloro-5-nitro-N-phenylbenzamide (GW9662), interfere with cancer cell metabolism, apoptosis, and migration, thereby enhancing their antitumor efficacy. Combination strategies involving chemotherapy, radiotherapy, or targeted therapies have shown synergistic effects, improving treatment response and overcoming resistance. Beyond direct tumor suppression, PPAR antagonists modulate immune responses and reshape the tumor microenvironment, offering a multifaceted therapeutic approach. Despite promising results, clinical translation remains limited and requires further studies to improve selectivity, pharmacokinetics, and drug delivery strategies. This review provides a comprehensive analysis of the medicinal chemistry, molecular mechanisms, and pharmacological development of PPAR antagonists, highlighting their potential clinical applications. Future efforts should refine drug design, develop personalized treatments, and conduct well-designed clinical trials to unlock their role in precision oncology.
2024-04-18·Cancer research communications
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Article
作者: Meredith A. McKean ; Thomas B. Karasic ; Chan C. Whiting ; Nathan Standifer ; Sam H. Whiting ; Mark Yarchoan ; Peppi Prasit ; Steven Smith ; Pamela N. Munster ; Yasser Ged ; Susanna V. Ulahannan ; Yvonne M. Saenger ; Robert Stagg ; Thomas W. Dubensky ; Oxana V. Crysler ; Leisha A. Emens ; Anne Moon ; Yonchu Jenkins ; Bruno R. Bastos ; John D. Powderly
Abstract:
Purpose::
TPST-1120 is a first-in-class oral inhibitor of peroxisome proliferator-activated receptor α (PPARα), a fatty acid ligand-activated transcription factor that regulates genes involved in fatty acid oxidation, angiogenesis, and inflammation, and is a novel target for cancer therapy. TPST-1120 displayed antitumor activity in xenograft models and synergistic tumor reduction in syngeneic tumor models when combined with anti-PD-1 agents.
Experimental Design::
This phase I, open-label, dose-escalation study (NCT03829436) evaluated TPST-1120 as monotherapy in patients with advanced solid tumors and in combination with nivolumab in patients with renal cell carcinoma (RCC), cholangiocarcinoma (CCA), or hepatocellular carcinoma. Objectives included evaluation of safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity (RECIST v1.1).
Results::
A total of 39 patients enrolled with 38 treated (20 monotherapy, 18 combination; median 3 prior lines of therapy). The most common treatment-related adverse events (TRAE) were grade 1–2 nausea, fatigue, and diarrhea. No grade 4–5 TRAEs or dose-limiting toxicities were reported. In the monotherapy group, 53% (10/19) of evaluable patients had a best objective response of stable disease. In the combination group, 3 patients had partial responses, for an objective response rate of 20% (3/15) across all doses and 30% (3/10) at TPST-1120 ≥400 mg twice daily. Responses occurred in 2 patients with RCC, both of whom had previously progressed on anti-PD-1 therapy, and 1 patient with late-line CCA.
Conclusions::
TPST-1120 was well tolerated as monotherapy and in combination with nivolumab and the combination showed preliminary evidence of clinical activity in PD-1 inhibitor refractory and immune compromised cancers.
Significance::
TPST-1120 is a first-in-class oral inhibitor of PPARα, whose roles in metabolic and immune regulation are implicated in tumor proliferation/survival and inhibition of anticancer immunity. This first-in-human study of TPST-1120 alone and in combination with nivolumab supports proof-of-concept of PPARα inhibition as a target of therapeutic intervention in solid tumors.
106
项与 Amezalpat 相关的新闻（医药）2026-09-18
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)-- Tempest Therapeutics, Inc.. (“Tempest”), a privately-held clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc.. (Nasdaq: MLND) (“Millendo”), announced today that they have entered into a definitive agreement under which Millendo will merge with Tempest in an all-stock transaction. The combined company will focus on advancing Tempest’s oncology pipeline of small molecule therapeutics that have the potential to address a wide range of tumors. Upon shareholder approval, the combined company is expected to operate under the name Tempest Therapeutics and trade on the Nasdaq Capital Market under the ticker symbol TPST.
In support of the merger, Tempest has secured commitments from a premier syndicate of healthcare investors comprised of Versant Ventures, Rock Springs Capital, F-Prime Capital, Monashee Investment Management, Quan Capital, Lyfe Capital, Maven Investment Partners US, Lilly Asia Ventures and Eight Roads Ventures for a $30 million PIPE financing that is expected to close concurrent with the completion of the merger. Together with the cash expected from both companies at closing, the net proceeds of the merger and financing are expected to fund the further development of Tempest’s three oncology programs and operate the company into early 2023. The financing and merger are expected to close in the first half of 2021.
“We are very pleased to announce this proposed merger with Millendo Therapeutics, which will facilitate the advancement of our broad pipeline of targeted oncology programs, including TPST-1495 and TPST-1120, which are both progressing in the clinic with encouraging early signs of clinical benefit,” said Tom Dubensky, Ph.D., chief executive officer of Tempest. “Together with our recently announced clinical collaboration with Roche to investigate TPST-1120 in a randomized frontline hepatocellular carcinoma study, this has been a highly productive quarter for Tempest that sets the stage for additional potential catalysts from our proprietary oncology programs. The transition of Tempest to a public company enhances our ability to fund these potentially important product candidates, as well as consider additional programs with exciting new targets.”
Tempest’s oncology pipeline is led by two clinical programs, TPST-1495 and TPST-1120, with broad potential across multiple tumor types. TPST-1495 is an antagonist selective for two receptors in the prostaglandin (PGE2) pathway, EP2 and EP4, which promote both tumor growth and the proliferation of suppressive immune cell populations. Tempest is currently evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of TPST-1495 in a multicenter Phase 1a/1b dose and schedule optimization study in patients with advanced solid tumors, with a focus on known prostaglandin-driven tumors such as colorectal cancer, lung adenocarcinoma and urothelial cancer. Tempest expects to report topline data from this study prior to the end of 2021, as well as data from planned monotherapy dose expansion and combination studies in 2022. TPST-1120 is designed to be a selective antagonist of proliferator-activated receptor alpha (PPAR⍺) which is a transcription factor that regulates the expression of target genes that promote angiogenesis and enable a cellular metabolic pathway known as fatty acid oxidation. TPST-1120 has completed monotherapy dose escalation and is progressing through a combination dose escalation study with nivolumab. This summer, Tempest expects F. Hoffmann-La Roche Ltd to initiate a global, randomized Phase 1b/2 clinical study in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic HCC not previously treated with systemic therapy, pursuant to a recently announced collaboration between the companies. Tempest expects to report topline data from this study by year-end 2022.
“Millendo Therapeutics’ strategic review was a thorough and thoughtful process. We believe we have found a partner that offers not only the greatest value for our existing shareholders but also promising targeted oncology product candidates for patients living with cancer,” said Louis Arcudi, chief executive officer of Millendo.
About the Proposed Merger
Millendo stockholders are expected to own approximately 18.5% of the combined company and pre-merger Tempest stockholders will own approximately 81.5% of the combined company. The percentage of the combined company that Millendo’s stockholders will own as of the close of the transaction is subject to adjustment based on the amount of Millendo’s net cash at the closing date.
Upon closing of the transaction, Millendo will be renamed Tempest Therapeutics, Inc. and will be headquartered in South San Francisco, CA. Stephen Brady and Tom Dubensky, Ph.D., will serve as chief executive officer and president, respectively, of the combined company. The merger agreement provides that the Board of Directors of the combined company will be comprised of seven members. The merger agreement has been approved by the Board of Directors of each company, and the transaction is expected to close in the first half of 2021, subject to approvals by the stockholders of each company, the effectiveness of a registration statement filed with the U.S. Securities and Exchange Commission to register the shares of Millendo common stock to be issued in connection with the merger, the completion of a PIPE financing, and other customary closing conditions.
SVB Leerink is serving as the exclusive financial advisor to Millendo and WilmerHale is serving as legal counsel. Piper Sandler is serving as the exclusive financial advisor to Tempest and Sidley Austin is serving as legal counsel.
Conference Call Information
Millendo and Tempest will host a conference call today, March 29, 2021, at 8:30 a.m. ET, to discuss the merger. The conference call may be accessed by dialing 1-(678) 302-3550 or 1-(866) 939-3921 internationally and referencing conference ID number 50135737. A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at and Tempest’s website at . A replay of the webcast will be archived on both company’s websites for 30 days following the presentation.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. For more information, please visit .
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an inhibitor of TREX-1, a double-stranded DNA exonuclease that is designed to control activation of the cGAS/STING pathway, which is an innate immune response pathway that induces the production of IFN-β, a cytokine that is well-established to trigger the development of anti-tumor immunity. Oral delivery of a TREX-1 small molecule inhibitor is intended to selectively activate STING in tumors, leading to anti-tumor immunity. Tempest is headquartered in South San Francisco and supported by notable healthcare investors. More information about Tempest can be found on the company’s website at .
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)) concerning Millendo, Tempest, the proposed transaction and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Millendo, as well as assumptions made by, and information currently available to, management of Millendo. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the conditions to the closing of the transaction are not satisfied, including the failure to obtain stockholder approval for the transaction or to complete the financing in a timely manner or at all; uncertainties as to the timing of the consummation of the transaction and the ability of each of Millendo and Tempest to consummate the transaction, including the PIPE financing; risks related to Millendo’s continued listing on the Nasdaq Stock Market until closing of the proposed transaction; risks related to Millendo’s and Tempest’s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the ability of Millendo or Tempest to protect their respective intellectual property rights; competitive responses to the transaction; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Millendo’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Millendo can give no assurance that the conditions to the transaction will be satisfied. Except as required by applicable law, Millendo undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
No Offer or Solicitation
This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.
Important Additional Information Will be Filed with the SEC
In connection with the proposed transaction between Millendo and Tempest, Millendo intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus of Millendo and information statement of Tempest. MILLENDO URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MILLENDO, TEMPEST, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Millendo with the SEC (when they become available) through the website maintained by the SEC at . In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Millendo with the SEC by contacting Stern IR. Investors and stockholders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.
Participants in the Solicitation
Millendo and its directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Millendo’s directors and executive officers is included in Millendo’s most recent Annual Report on Form 10-K, including any information incorporated therein by reference, as filed with the SEC, and the proxy statement for Millendo’s 2020 annual meeting of stockholders, filed with the SEC on April 24, 2020. Additional information regarding these persons and their interests in the transaction will be included in the proxy statement/prospectus/information statement relating to the transaction when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
View source version on businesswire.com:
First in Class小分子药物并购
2026-09-18
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced today the closing of its merger with Millendo Therapeutics, Inc. (“Millendo”). Tempest’s stock will commence trading on June 28, 2021 on the Nasdaq Global Select Market under the trading symbol “TPST.”
In support of the merger, Tempest secured investments from a premier syndicate of healthcare investors composed of Versant Ventures, Rock Springs Capital, F-Prime Capital, Monashee Investment Management, Quan Capital, Lyfe Capital, Maven Investment Partners US, Lilly Asia Ventures and Eight Roads Ventures for a $30 million PIPE financing that closed concurrent with the completion of the merger. The net proceeds of the transaction are expected to fund the company’s operations and advancement of its programs into early 2023, including:
“The closing of this merger fulfills an important 2021 goal for Tempest,” said Steve Brady, chief executive officer of Tempest. “With our novel programs, including TPST-1495 and TPST-1120 progressing in the clinic, access to the public markets was of strategic importance as we look forward to a number of potential catalysts in the future and advance towards our goal to offer patients with cancer meaningful therapeutic options.”
Transaction Terms and Leadership Team Updates
In connection with the closing of the merger, Millendo effected a 1:15 reverse split of its common stock. Tempest has approximately 6.7 million shares of common stock outstanding after giving effect to the terms of the transaction. Tempest stockholders prior to the merger, combined with investors in the concurrent financing, collectively own approximately 81% of the outstanding shares, and prior Millendo stockholders own approximately 19% of the outstanding shares.
Effective as of the closing of the merger, Geoff Nichol, chief medical officer of BioMarin, and Steve Brady, chief executive officer of Tempest, are joining Mike Raab, president and chief executive officer of Ardelyx, Tom Woiwode, managing director, Versant Ventures, Tom Dubensky, president of Tempest, and Stella Xu, managing director, Quan Capital, on the Tempest board of directors.
Piper Sandler served as the exclusive financial advisor and placement agent to Tempest, and Sidley Austin served as Tempest’s legal counsel. SVB Leerink served as the exclusive financial advisor to Millendo and WilmerHale served as Millendo’s legal counsel.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco and supported by notable healthcare investors. More information about Tempest can be found on the company’s website at .
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)) concerning Tempest Therapeutics. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: our strategies, prospects, plans, expectations or objectives for future operations; the progress, scope or timing of the development of our product candidates; the benefits that may be derived from any future products or the commercial or market opportunity with respect to any of our future products; our ability to protect our intellectual property rights; our anticipated operations, financial position, ability to raise capital to fund operations, revenues, costs or expenses; statements regarding future economic conditions or performance; statements of belief and any statement of assumptions underlying any of the foregoing. Many of these risks are described in greater detail in the proxy statement/prospectus filed by Millendo Therapeutics with the Securities and Exchange Commission relating to the merger. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Contacts:
Sylvia WheelerWheelhouse Life Science Advisorsswheeler@wheelhouselsa.com
Alex SantosWheelhouse Life Science Advisorsasantos@wheelhouselsa.com
First in Class小分子药物并购
2026-09-17
2026年9月15日美东时间16:05，位于美国加州Brisbane的临床期生物技术公司Tempest Therapeutics（Nasdaq: TPST）通过GlobeNewswire发布新闻稿，宣布与中国河北森朗生物科技有限公司（Hebei Senlang Biotechnology）签署独家选择权协议（exclusive option agreement），获得后者CD7靶向慢病毒（lentiviral vector, LV）平台及一系列体内CAR-T（in vivo chimeric antigen receptor T cell）候选药物在中国以外地区的授权选择权，森朗保留中国区权益。该新闻稿同时作为SEC 8-K文件Exhibit 99.1提交EDGAR，行业媒体Citeline Scrip将其称为"中国首个体内CAR-T全球出授权交易"。
新闻稿披露的临床信号非常克制：截至2026年8月25日，核心资产——BCMA/GPRC5D双靶向体内CAR-T——在复发/难治性多发性骨髓瘤（relapsed/refractory multiple myeloma, R/R MM）I期剂量递增试验的"当前最高可评估剂量"下，观察到体内CAR-T成功生成与扩增，未观察到≥3级细胞因子释放综合征（cytokine release syndrome, CRS）或免疫效应细胞相关神经毒性综合征（immune effector cell-associated neurotoxicity syndrome, ICANS）。受此消息驱动，TPST在9月16日盘前一度上涨49.6%至1.13美元，Benzinga记录了这一异动，当日收涨60.18%至1.21美元，但盘后迅速回吐10.7%至1.08美元。
一句话核心判断：这不是一笔重磅BD交易，而是一家中国中小型CAR-T公司用"体内CAR-T概念"换取美国一家现金枯竭的微盘Biotech股价上涨的双向选择权交易——Tempest用一张"待兑现的期权"博一张更远的期权，森朗用技术数据包披露换取纳斯达克曝光与"中国首单"品牌标签。真正的价值兑现，要等到Tempest能否在未来12–18个月内融到钱或被MNC收购。
本文不打算复述新闻稿，而是主动找问题、挑毛病：交易条款为什么不披露？为什么在ClinicalTrials.gov和ChiCTR查不到对应的体内CAR-T试验？Tempest的资产负债表能否支撑它行权？森朗的CD7-LV平台专利在哪里？与已经被Eli Lilly以最高70亿美元收购的Kelonia、被Kite/Gilead以3.5亿美元现金收购的Interius相比，森朗的差异化究竟在哪里？全文将区分"已查证事实"、"公司自述"与"基于对标交易的估算"，所有关键数字均给出信源。
需要把这笔交易放回2026年体内CAR-T资本浪潮的大背景中。过去十八个月，这个曾经只在学术会议上被讨论的概念，已经被大型药企用真金白银重新定价：Eli Lilly在2026年4月以最高70亿美元吞下Kelonia，AbbVie在2025年6月以约21亿美元收购Capstan，Gilead旗下Kite在2025年8月以3.5亿美元现金收购Interius，阿斯利康在2025年3月以首付4.25亿美元牵手EsoBiotec，Gilead旗下Kite又在2025年10月以1.64亿美元headline对价牵手深圳普瑞金。这一连串交易传递的信号非常清晰：MNC判断"把基因递送工具直接注射进人体、在患者体内现场制造CAR-T"是下一代细胞治疗的范式转折点。Tempest与森朗的交易，正是在这股浪潮末期发生的——它不是开创者，而是追赶者；它也不是MNC主导的重磅收购，而是一家美国微盘股与一家中国中小Biotech之间的"故事互换"。理解这一时点，是理解全文所有判断的前提。
我们还要预先说明一个方法论立场。生物医药行业的新闻稿天然具有"选择性披露"倾向：只讲阳性信号、不讲阴性细节；只讲平台愿景、不讲数据缺口；只讲交易 headline、不讲财务条款。本文的写作目标不是替任何一方做宣传，而是把新闻稿里被隐去的数字、被模糊处理的试验注册号、被过度延伸的"首创"叙事，一项一项摊开在阳光下。读者会看到大量"未披露""无法核实""公司自述"的标注——这不是写作的失败，恰恰是这类早期BD交易最真实的样貌。
第一章 新闻主张vs 核实结果1.1 交易真实性与法律性质
交易本身真实存在。一手信源有三：(1) Tempest官方GlobeNewswire新闻稿；(2) 同稿作为SEC 8-K Ex-99.1提交EDGAR（CIK 0001544227）；(3) Citeline Scrip 9月16日深度报道。但必须强调：法律性质是"选择权（option）"而非"正式授权（license）"——Tempest可以在期权期内（通常12–24个月）以极低行权成本放弃交易，权利自动回归森朗。1.2 交易条款：全部财务数字均未披露
逐字核对新闻稿与8-K全文，仅可确认非财务条款：协议类型为独家选择权；标的为CD7靶向慢病毒平台+体内CAR-T组合；主导资产为BCMA/GPRC5D双靶体内CAR-T；地域为ex-China，森朗保留中国权益。而选择权费、行权价、开发/监管/商业里程碑总额、royalty比例、期权有效期、最低开发承诺、技术转移安排，全部未披露。
红旗：对一家市值约1200万美元、现金仅百余万美元的公司，"未披露"几乎可合理推断为选择权费极低甚至仅以股权/象征性现金对价支付——否则在8-K中必然以material agreement形式披露。Tempest真正押注的是"用期权换取平台曝光、用股价上涨进行ATM增发融资"的财务逻辑。1.3 临床试验注册缺失：本次核查最严重的事实模糊点
新闻稿称BCMA/GPRC5D双靶体内CAR-T"正在中国进行I期剂量递增"。但我们在ClinicalTrials.gov与ChiCTR逐一排查后，未找到Sponsor为Hebei Senlang、对应"体内无需细胞采集"路线的注册试验。市场上流传的ChiCTR2500112124经原文核对，实为华中科技大学同济医院与广州百暨基因合作的体外自体BCMA/GPRC5D CAR-T试验——其纳入标准第10条明确要求"可建立采集所需的静脉通路，无白细胞采集禁忌症"，干预措施为"接受BCMA/GPRC5D CAR-T细胞的输注和治疗"，与森朗"体内、原位生成CAR-T/CAR-NK"的技术叙事完全不符。
红旗："I期剂量递增进行中"目前只能视为公司自述（company-reported）。任何严肃尽调必须直接索取：(a) NMPA临床试验默示许可号或IIT伦理批件号；(b) ChiCTR/ClinicalTrials.gov注册号；(c) 已入组患者数、剂量水平、清淋方案。1.4 股价数据核实与基本面
时间（美东）
价格
涨跌幅
信源
9/15收盘
$0.7554
-3.68%
雪球
9/16盘前
$1.13
+49.6%
Benzinga
9/16收盘
$1.21
+60.18%
Barchart
9/16盘后
$1.08
-10.74%
StockAnalysis历史数据
必须同时指出：TPST是一只从52周高点12.23美元跌至0.75美元的深度下跌股，50%涨幅仅相当于从0.75回到1.13，仍较高点下跌约90%。市值仅约1200万美元，9月11日刚以0.805美元行权价完成250万美元急救式私募。1.5 Tempest财务困境：持续经营重大不确定性
根据Tempest 2026Q2 10-Q，现金及现金等价物从2025年末的770.7万美元降至2026-03-31的224.8万美元，再降至2026-06-30的约78万–122万美元（两份研究报告因是否计入受限现金口径略有差异），总负债约1072万美元，2026上半年经营活动现金流净流出约1040万美元，股东权益已转负。10-Q明确表述："现有现金…将在财务报表发布日起12个月内无法满足预计经营支出…公司持续经营能力存在重大不确定性（substantial doubt about going concern）。"1.6 森朗工商背景
据企查查，河北森朗生物科技有限公司成立于2016年1月29日，法定代表人丁伟，创始人/CEO郭胜敏持股34.85%，联合创始人李建强博士持股16.33%，注册资本约1176万元人民币，参保约120人。核心资产SENL101（CD7纳米抗体自体CAR-T，NMPA IND 2023LP01119，CDE突破性治疗品种，FDA孤儿药资格）已有60例长期随访数据发表于Blood；SENL103（BCMA自体CAR-T）2025年获默示许可。公司自述授权国家发明专利13件、PCT 3件。这是一家成立近10年、以CD7为差异化赛道的中小型中国CAR-T公司，尚未有产品上市。1.7 双向合作：这不是单向授权，而是"平台互换"
市场报道容易忽略一个关键事实：在2026年9月15日交易之前，双方已经在2026年7月21日有过一次方向相反的合作。当天Tempest同样通过GlobeNewswire与SEC 8-K披露，双方就TPST-4003达成开发合作——TPST-4003是Tempest自有CD7靶向mRNA/LNP平台、搭配CD19/BCMA双靶CAR结构的体内候选物，森朗在中国牵头开展约10例重症肌无力（MG）与多发性硬化（MS）患者的研究者发起试验（IIT），首例给药预计2026年第四季度，初步安全与药效数据预计2027年上半年。
但这次合作的合同方向与9月15日交易恰好相反：7月21日是Tempest把TPST-4003中国区权益的独家谈判选择权授予森朗；9月15日是森朗把CD7慢病毒平台的ex-China选择权授予Tempest。双方实质上在进行一次"平台互换"——Tempest出LNP平台的中国人体数据机会，森朗出LV平台的海外商业化选择权。理解这一层，才能理解为什么两家公司都愿意在财务条款几乎不披露的情况下官宣：双方都需要一个"跨洋合作"的故事来支撑各自的资本市场叙事，至于现金对价，反而是次要的。1.8 森朗的既往出海与本次交易的量级对比
森朗并非首次出海。2023年4月，公司曾将BCMA自体CAR-T授权给韩国VaxcellBio，覆盖韩国市场。但那是一个单国、体外自体CAR-T、金额未公开的小型交易。本次与Tempest的选择权，在地域范围（ex-China）、技术形态（体内LV平台）、交易对手（纳斯达克上市公司）三个维度上都显著升级。但升级不等于重磅——选择权结构本身就把"升级"的财务含金量大幅稀释了。对森朗而言，真正的价值不在于收到多少option fee，而在于借助Tempest的纳斯达克身份，把"中国首个体内CAR-T出授权"这一标签写进自己下一轮中国融资或IPO的BP里。
第二章 科学与技术批判性分析2.1 CD7靶向体内递送的生物学问题
CD7是免疫球蛋白超家族I型跨膜糖蛋白，在外周血约95%的CD3+ T细胞、约80%的CD56+ NK细胞以及部分单核细胞、小肠上皮基底层表达。静息T细胞CD7高表达，正是体内CAR-T想转导的细胞群；但CD7在T细胞完全活化后快速下调，NK细胞CD7表达也呈强异质性（CD56dim高、CD56bright低）。
传统CD7 CAR-T的核心难题是"自相残杀（fratricide）"——CAR-T细胞自身也表达CD7。森朗在体外路线上用"自然选择（NS7CAR）"筛选CD7-low T细胞解决这一问题。但在体内递送场景下，fratricide不再是核心矛盾，真正的问题被转移了：
第一，正常CD7+ T/NK细胞被"误编辑"。静脉注射后，凡遇CD7+细胞即转导，除了"将来要变成CAR-T的细胞"外，大量旁观者CD7+ T细胞也会被插入BCMA/GPRC5D CAR转基因。这些旁观者在没有肿瘤抗原刺激时处于静息状态，但若日后遇到自身抗原，会以CAR形式异常激活——自身免疫与脱靶毒性风险被放大。第二，正常T/NK细胞库多样性受损，相当于在体内进行一次非受控的自体CAR-T制造。第三，NK细胞对慢病毒天然转导效率低（受SAMHD1等宿主限制因子），需要Vpx或颗粒蛋白工程化，森朗未提及如何克服。2.2 慢病毒载体体内递送的六重技术风险
新闻稿披露的平台三大工程化特征为：纳米抗体retargeting、工程化detargeted cocal envelope、producer-cell immune-shielding。这与学术文献中的TaSEL（麻疹/海豚瘟病毒H/F糖蛋白+αCD7 VHH）和"stealth LV"（CD47过表达+MHC-I KO）路线高度同构——技术有学术可行性，但并非森朗独创。具体风险包括：
(a) 脱靶转导：CD7在小肠上皮、部分胶质细胞、视网膜光感受器低水平表达；IV首过效应在肺，detargeting不完全时肝/Kupffer细胞可能被低水平转导。新闻稿未披露脾/肝/肺/骨髓/生殖腺的vg/cell生物分布数据。
(b) 插入突变与致瘤性：慢病毒相比γ-逆转录病毒致白血病风险显著降低，但仍优先整合在转录活跃基因5'调控区。体外CAR-T先分选T细胞再转导，整合事件可控；体内递送直接把载体注射给患者，所有被转导的CD7+细胞——包括静止记忆T细胞，若CD7低表达波及造血干/祖细胞——都会发生整合。一旦发生HSC水平整合，致瘤风险将接近基因治疗范畴，需要10–15年长期随访。
(c) RCL检测：复制型慢病毒（replication-competent lentivirus, RCL）一旦在患者体内产生，无法像体外CAR-T那样通过洗涤去除。新闻稿未提及RCL检测方案与灵敏度（行业通常要求≤1 RCL/3×10¹⁰ TU）。
(d) 补体清除与预存免疫：VSV-G包膜人群预存中和抗体阳性率约30%–60%；cocal病毒与人类无共流行，预存免疫低，这是森朗选cocal的核心rationale。但若使用麻疹H/F路线，中国1970年后出生人群麻疹疫苗接种率高，需用海豚瘟病毒嵌合包膜逃逸——森朗未公开其cocal是否做了类似改造。
(e) 生殖系整合：IV给药后载体可分布至卵巢/睾丸，所有体内基因治疗产品均要求治疗后12个月避孕，新闻稿未提。(f) 肺首过毒性：IV后肺内皮是否被转导是体内LV常见隐患。2.3 BCMA/GPRC5D双靶点的科学依据与隐患
BCMA（CD269）是MM浆细胞已验证靶点，已被Abecma（ide-cel）和Carvykti（cilta-cel）证明；但BCMA低表达或丢失是CAR-T治疗后复发主因（约60%复发患者出现BCMA下调）。GPRC5D在MM浆细胞上独立表达，talquetamab（J&J，2023年FDA批准）已验证成药性。双靶设计理论上可覆盖BCMA阴性复发、降低抗原逃逸。
但GPRC5D的on-target/off-tumor毒性是核心隐患：GPRC5D表达于皮肤毛囊上皮、指甲硬角化组织、舌丝状乳头、掌跖皮肤。Talquetamab临床中味觉障碍72.8%、指甲病变50%、皮肤反应41%；更严重的是BMS-986393（GPRC5D CAR-T）最高剂量组观察到2/16患者出现持续性小脑综合征。体外CAR-T的这类毒性可通过停药、激素控制；体内CAR-T的CAR一旦整合入T细胞基因组，将终生表达，GPRC5D介导的皮肤/神经毒性可能成为永久性。2.4 体内 vs 体外CAR-T的根本差异
维度
体外自体CAR-T（Abecma/Carvykti）
体内CAR-T（森朗/Kelonia路线）
细胞来源
白细胞单采、体外激活转导扩增回输
直接IV注射LV，原位转导内源T/NK
生产周期
4–6周
单次注射即刻
剂量控制
可精确控制CAR+细胞剂量
受基线CD7+细胞数、转导率、肿瘤负荷三变量影响
可终止性
可停药/开关/激素控制
基因组整合，终身持续
清淋化疗
必需（flu/cy）
Kelonia宣称不需要；森朗未明确
长期致瘤数据
约10年随访，未见LV致瘤信号
人体长期数据<5年，未排除
体内CAR-T的剂量控制难题是I期设计核心：DLT取决于"患者体内CD7+ T细胞数×转导率×肿瘤负荷"三个变量，在多线治疗淋巴细胞减少的MM患者与初诊患者间可能产生数量级差异的CAR-T扩增。2.5 CAR-NK附加价值：更多是营销叙事
新闻稿强调平台"同时生成CAR-T和CAR-NK"。但NK细胞体内寿命仅1–4周，无法像T细胞形成长期免疫记忆；全球CAR-NK在MM中的ORR数据远不及CAR-T；NK对LV天然抗性需特殊工程化。"同时生成CAR-T和CAR-NK"听起来比"仅生成CAR-T"更具颠覆性，但实际疗效贡献在MM中未被验证，投资者不应为CAR-NK概念支付溢价。2.6 技术非独创性：与Interius/TaSEL路线同构
这是本次尽调最被市场忽视的一点。森朗CD7装饰LV靶向T/NK细胞的路线，与2024年10月已在澳洲完成全球首例体内CAR-T给药、后被Kite/Gilead以3.5亿美元现金收购的Interius INT2104（CD7装饰LV编码抗CD20 CAR，同时靶向T与NK）概念上几乎同构；学术层面TaSEL平台（MeV融合糖蛋白+αCD7 VHH）也高度相似。这意味着森朗平台在IP上必须回答：与Interius（现Kite/Gilead）的CD7-LV专利家族是否存在FTO冲突？2.7 体内递送剂量与转导率的未披露难题
新闻稿使用"single low-dose administration"（单次低剂量给药）这一模糊表述，但"低剂量"是相对什么而言？体外CAR-T转导1位患者的T细胞，通常需要10⁸–10⁹转导单位（TU）；而体内直接静脉注射，因载体进入血液后会被补体、吞噬细胞、预存抗体层层清除，真正到达T细胞表面并完成转导的比例往往不到1%。行业共识是体内给药所需载体剂量比体外转导高1–2个数量级，即10¹⁰–10¹¹ vg/剂级别。森朗未披露其给药剂量（vg/kg或TU/kg），也未披露给药后患者外周血中CAR基因拷贝数峰值（vector copies/μg genomic DNA）——这两个数字是判断"体内是否真的生成了足够数量CAR-T"的最低门槛。没有这两个数字，"成功生成并扩增"这句话在科学上是不完整的。
另一个未披露的关键问题是转导细胞的表型。体外CAR-T在OKT3/CD3/CD28磁珠激活后扩增，最终产品偏向效应记忆（TEM）和终末效应（EMRA）表型，耗竭标志物PD-1/TIM-3/LAG-3表达较高；而体内未经体外扩增的T细胞，理论上更接近初始（naive）和干细胞样记忆（TSCM）表型，这本来是体内路线的卖点——更年轻、更持久。但这一理论优势在人体中尚未被严格验证。Kelonia KLN-1010在2025 ASH全体报告中观察到体内CAR-T的扩增动力学与体外产品相似（Tmax约10–14天），但记忆表型比例、耗竭标志物数据未在公开摘要中详细披露。森朗连CAR+细胞比例都未披露，表型数据完全缺失。2.8 抗原内吞与双CAR信号平衡
BCMA是I型跨膜受体，与CAR结合后内吞速率较快，CAR信号强度需要精细调节以避免T细胞耗竭；GPRC5D是七次跨膜的G蛋白偶联受体，其内吞动力学、下游信号通路与BCMA完全不同。双CAR结构若共用同一个4-1BB或CD28共刺激域，两个靶点信号强度的平衡是一个工程难题——BCMA高表达时信号过强导致CRS/耗竭，GPRC5D高表达时信号过弱导致无效激活。森朗未公开其双CAR是串联（tandem）、双顺反子（bicistronic with 2A peptide）还是双载体设计，也未公开共刺激域选择。这些工程细节决定了产品的安全性窗口，但在新闻稿中被完全省略。
第三章 临床设计、疗效与安全性分析3.1 I期剂量递增设计的已知与未知
由于试验未在ClinicalTrials.gov/ChiCTR公开登记，以下关键设计参数全部未知：剂量爬坡方法（3+3/BOIN/mTPI-2）、起始剂量与步长、清淋方案、DLT窗口、MTD/RP2D规则、是否纳入既往BCMA靶向治疗经治患者、ECOG与脏器功能标准。直接对标Kelonia KLN-1010（NCT07075185，inMMyCAR）已在2026 ASCO摘要#260448和2025 ASH全体报告中公开剂量、入组人数、CRS分级与初步M蛋白变化。森朗数据披露颗粒度显著低于行业标准。
两个潜在设计红旗：(1) 新闻稿未提"不使用清淋化疗"——若森朗仍要求flu/cy，相对Kelonia"无清淋"的差异化优势大打折扣；(2) 未提是否允许既往BCMA CAR-T经治患者——若仅入组未用过BCMA靶向治疗者，"克服抗原逃逸"卖点无法验证。3.2 疗效评估的根本局限
"体内CAR-T成功生成并扩增"只是可行性验证第一步，不等于：CAR-T是否有抗肿瘤活性、是否到达骨髓（MM主要庇护所）、是否诱导M蛋白下降、是否产生MRD阴性深度缓解。新闻稿逐字为："Early clinical observations at the current highest evaluable dose demonstrate successful generation and expansion of CAR-T cells in vivo…no Grade 3 or higher CRS and no ICANS."关键缺失：入组人数、具体剂量（vg/kg）、CAR-T峰值比例（CD3+CAR+%）、CAR基因拷贝数、扩增动力学Tmax、任何疗效指标（M蛋白、骨髓浆细胞、ORR、VGPR、MRD）、CRS总发生率与tocilizumab使用、清淋方案、最长随访。
"截至2026-08-25"数据截点，若首例给药在2026 Q1–Q2，最长随访仅3–6个月。MM CAR-T关键疗效指标通常需回输后1–3个月评估，早期随访无法判断持久性。3.3 安全性数据的批判性审视
"无≥3级CRS、无ICANS"在小样本早期数据中真实意义有限：(1) 若按3+3设计，第一剂量水平仅3例，3例中无≥3级CRS的95% Clopper-Pearson置信区间上限高达56%；(2) 剂量递增尚未完成，MTD未达，真正毒性通常在高剂量显现；(3) 体内CAR-T因需时间转导扩增，CRS可能延迟至10–14天甚至更晚；(4) ICANS需专用ICE评分与脑脊液分析，森朗未披露。长期风险包括插入突变（潜伏期3–15年）、RCL、迟发性CRES/PRES、B细胞再生障碍（需终身IVIG替代）。3.4 与已上市MM CAR-T安全性对比
产品
任意级CRS
≥3级CRS
任意级ICANS
≥3级ICANS
Abecma（KarMMa-3 N=349）
89%
7%
~28%
<5%
Carvykti（CARTITUDE-1 N=97）
95%
5%
23%
3%
泽沃基奥仑赛（CT103A，中国）
~95%
~5%
~10%
<3%
森朗体内BCMA/GPRC5D
未披露
0%（样本量未知）
0%
0%
已上市BCMA CAR-T的≥3级CRS率约5%–7%、≥3级ICANS约2%–3%。森朗"无≥3级CRS、无ICANS"在小样本下与已上市产品不可比——不是因为它更安全，而是样本太小、剂量可能仍在亚治疗水平、且若未做清淋CAR-T扩增有限。真正的安全性优势应体现为：在产生≥VGPR深度缓解的同时，≥3级CRS/ICANS率低于已上市产品。目前森朗连疗效数据都没有。3.5 清淋化疗之争：体内CAR-T的"可及性"叙事能否成立
体内CAR-T对资本市场最大的故事吸引力，是"无需白细胞单采、无需4–6周生产周期、可在社区医院静脉给药"。但这个故事成立的前提之一，是真的可以省略氟达拉滨+环磷酰胺（flu/cy）淋巴清除化疗。Kelonia KLN-1010的一个关键卖点正是"临床前数据显示无需淋巴清除"，但即使如此，其人体试验方案是否真的完全省略了flu/cy，仍需在公开protocol中确认。Interius、EsoBiotec、Umoja的临床方案则普遍仍要求flu/cy预处理，理由是：体内生成的CAR-T细胞需要在一个"腾出来的"淋巴空间中才能有效扩增，否则与宿主淋巴细胞竞争资源，扩增不足。
森朗新闻稿对清淋方案只字未提。这是一个决定性的设计变量：如果森朗仍要求flu/cy清淋，那么"社区医院IV给药"的叙事直接破产——flu/cy本身需要住院监测、需要支持治疗、有骨髓抑制感染风险，与"门诊小注射"相去甚远。如果森朗真的做到了无清淋，这应该是新闻稿重点强调的差异化卖点，而不是被省略。沉默本身就是一个信号。3.6 长期随访与迟发性毒性
体内LV给药的长期安全性框架与体外CAR-T根本不同。体外CAR-T的T细胞在体外经过严格筛选、转导、扩增、质检后回输，整合事件数量可控；体内CAR-T则是把载体直接注入患者血液，所有被转导的细胞都发生基因组整合。FDA对所有体内基因治疗产品（如Zolgensma、Hemgenix）均要求上市后5–15年长期随访，重点监测插入突变导致的继发恶性肿瘤、RCL相关病毒血症、迟发性免疫病理。森朗目前最长随访仅3–6个月，距离能排除这些风险还有十年级别。任何把"目前无严重不良事件"解读为"安全性已验证"的报道，都混淆了"短期未见"与"长期排除"这两个完全不同的科学命题。
第四章 全球专利保护与FTO分析4.1 森朗专利组合梳理与关键缺口
基于企查查、水滴信用、智慧芽Synapse检索，森朗已公开专利集中在：CN116715766B（靶向CD7纳米抗体，2025-01-14授权，用于体外SENL101）、新一代抗CD7 VHH12（2025-11-12授权）、CN202011208669.1（抗CD7人源化抗体）、抗CD123纳米抗体CAR等。公司自述13件授权发明专利、3件PCT、8件实用新型。
关键缺口：本次交易最核心的"CD7靶向慢病毒载体/detargeted cocal envelope/producer-cell immune-shielding/BCMA-GPRC5D双靶CAR结构"，未检索到任何公开专利号。在Google Patents/USPTO/WIPO以"Hebei Senlang"为申请人检索，未发现2024–2026年新公开的病毒载体工艺PCT申请。这意味着核心平台IP可能：(a)仍在18个月保密期；(b)以商业秘密保护；(c)实际尚未申请；(d)与大学合作开发，核心专利在学术机构手中。4.2 地域覆盖错配
Tempest获得的是ex-China选择权，行权后要在美国商业化。但森朗已公开CD7 VHH专利仅中国授权明确，3件PCT是否进入美/欧/日国家阶段未确认——考虑到森朗此前仅将BCMA CAR-T授权韩国，其海外布局可能以东亚为主。若森朗核心专利未在美/欧/日布局，Tempest行权后在美商业化将"有技术、无专利墙"裸奔——竞争对手可自由实施（只要不侵犯他人专利）。4.3 FTO风险矩阵
Tempest现金状况、临床数据缺失、专利缺口三类风险处于红色高风险区，是行权前必须优先解决的事项；地缘政治与商密泄露虽短期概率较低，但一旦发生将对交易结构产生颠覆性影响。
体内CAR-T底层专利高度集中：(a) Kelonia/Lilly iGPS平台（anti-CD3 scFv改造包膜）与UT Southwestern学术专利；(b) Paul-Ehrlich-Institut的麻疹H/F retargeting底层专利；(c) cocal envelope相关专利原始持有人Mayo Clinic/UTMB；(d) CD47"don't eat me"基础专利（Stanford，现可能在BMS/Surface Oncology手中）；(e) Oxford BioMedica慢病毒包装细胞系专利（Carvykti原CDMO）；(f) BCMA/GPRC5D CAR结构专利墙（J&J/传奇、BMS/2seventy、Caribou）；(g) 更关键的是——与Interius INT2104同构的CD7装饰LV专利家族已随Interius归入Kite/Gilead。森朗必须回答：其CD7 VHH连接子设计、cocal detargeting、CD47 shielding组合，是否落入Kite/Gilead或Kelonia/Lilly的上位权利要求？4.4 中国专利海外可执行性
中国专利在美国执行需通过USITC或联邦地区法院诉讼，成本数百万美元；PCT进入美/欧/日国家阶段每件需数万至数十万美元维护费，森朗作为中小型Biotech是否有能力承担；中国发明专利权利要求撰写质量（尤其上位概念、马库什结构）普遍弱于美国；2026年中美生物科技脱钩背景下，若涉及美国政府资金支持还可能触发Bayh-Dole或CFIUS式审查。
还有一个容易被忽视的问题：森朗与北大人民医院、河北医科大学等学术机构的合作开发协议中，SENL101的NS7CAR技术源自陆道培团队在Blood发表的学术论文。这类合作研究通常约定"学术机构享有背景IP、森朗享有产品IP"，但具体权利要求的边界、改进发明的归属、是否存在共有专利，都需要在尽调中逐份核查。若森朗核心专利中有任何一件的权利人包含大学或公立医院，Tempest行权后将面临"需要与大学协商再许可"的复杂局面——这在生物医药BD尽调中是常见的权属瑕疵。
第五章 全球同类技术与管线竞争
过去18个月，体内CAR-T领域已发生约179亿美元headline交易。巨头已经完成卡位，Tempest在时点上落后至少12–18个月。下图汇总2025–2026年主要体内CAR-T交易的对价规模。5.1 全球主要玩家全景
公司
核心资产
递送技术
CAR靶点
适应症
阶段
BD事件
Kelonia（Lilly）
KLN-1010
iGPS工程化LV（CD3靶向）
BCMA
R/R MM
I期
Lilly 2026-04，最高$70亿
EsoBiotec（AZ）
ESO-T01
ENaBL纳米抗体装饰LV
BCMA
R/R MM
I期
AZ 2025-03，$10亿
Umoja
UB-VV111/400
VivoVec CD3靶向LV+RACR开关
CD19/CD22
B-NHL/CLL
I期
与AbbVie/驯鹿合作
Interius（Kite/Gilead）
INT2104
CD7装饰LV
CD20
B-NHL
I期（全球首例）
Kite 2025-08，$3.5亿现金
Capstan（AbbVie）
CPTX2309
CD8抗体装饰LNP（瞬时）
CD19
自免SLE/RA/MS
I期健康志愿者
AbbVie 2025-06，~$21亿
Sana
SG293（体内）
CD8靶向fusosome（非病毒）
CD19
自免
临床前（NHP）
NASDAQ:SANA
Myeloid
MT-302/303
mRNA-LNP（CAR-M）
TROP2/GPC3
实体瘤
I期
与AbbVie合作
Ensoma
EN-374
engEx VLP（CD47靶向HSC）
CYBB/CAR
基因病/自免
I/II期
与Takeda/Pfizer合作
Pregene（普瑞金）
多靶点LV平台
体内LV
多靶点
血液瘤/自免
临床前-IIT
Kite 2025-10，$1.64亿headline
科济药业
KJ-C2529
CARvivo体内平台
CD19/CD20
B-NHL
IIT 2026启动
2171.HK自研
森朗（本次）
BCMA/GPRC5D双靶
CD7靶向LV
BCMA/GPRC5D
R/R MM
I期（中国）
Tempest 2026-09选择权5.2 技术路线三分天下，森朗走最重一条
慢病毒体内（LV-in-vivo）：Kelonia、EsoBiotec、Umoja、Interius、森朗、Pregene、科济。优点是基因组整合、持久表达、一次给药；缺点是CMC极难、RCL监管负担重、抗载体免疫。LNP-mRNA体内：Capstan、Tempest自有TPST-4003、Myeloid。优点是瞬时表达、可重复给药、复用新冠疫苗供应链；缺点是表达持续时间短（天–周级），MM这种需持久记忆的适应症可能不够。非病毒VLP/fusosome/HSC工程：Sana SG293、Ensoma。差异化最强但临床成熟度最低。5.3 中国玩家的真实位势
PharmaDossier统计全球23个已注册体内CAR-T临床试验中19个（82.6%）由中国机构发起，但这数字有误导性——绝大多数是单中心、个位数患者的早期IIT，真正进入国际多中心IND阶段的中国资产只有Umoja/驯鹿UB-VV400（FDA IND）、Pregene（Kite合作）、森朗（本次选择权）、科济KJ-C2529（IIT）。中国的优势是"试验速度"而非"全球开发能力"。5.4 适应症红海：为什么BCMA/GPRC5D双靶MM是"红海中的红海"
森朗选择BCMA/GPRC5D双靶R/R MM作为先导适应症，从科学角度合理——这是体外CAR-T已经验证过的靶点组合。但从竞争角度看，这是一个已经非常拥挤的战场：Kelonia KLN-1010（BCMA单靶体内LV）已在2025 ASH全体报告披露18/18患者数据，2026 ASCO摘要进一步更新；EsoBiotec ESO-T01（BCMA单靶体内LV）已进入I期；BMS/2seventy的pumitamig（BCMA×GPRC5D双靶体外CAR-T）已进入关键注册阶段；J&J的talquetamab（GPRC5D×CD3双抗）2023年已获批并快速扩张后线市场；teclistamab、elranatamab等BCMA双抗正在把MM后线治疗从"一次性CAR-T"拉回"每季度打针"的慢性模式。森朗的差异化仅在于"体内+双靶"——但GPRC5D双靶在体外CAR-T中已被证明优于BCMA单靶，体内版本的双靶是否真能转化为临床获益，目前没有任何人体数据。
更严峻的是时点。当Kelonia已经被Lilly以70亿美元收购、Interius已经被Kite收购、Pregene已经拿到Kite 1.2亿首付时，森朗选择在2026年9月通过一家现金枯竭的美国微盘股出海，本身就说明它此前未能直接与MNC谈成重磅交易。这一点必须被冷静面对：在体内CAR-T这个赛道，头部资产已经被瓜分完毕，森朗能拿到的交易对手，是剩下的"需要故事续命"的小公司。5.5 森朗的竞争定位：差异化有限
把森朗放在全球坐标系中，它的所谓"差异化"可以归纳为三点：CD7靶向（而非CD3靶向）、同时生成CAR-T与CAR-NK、BCMA/GPRC5D双靶。但第一点与Interius INT2104同构，而Interius已被Kite收购；第二点在MM中的疗效未被验证，更多是营销叙事；第三点在体外CAR-T中已被BMS pumitamig等领先。森朗并不拥有一个全球独有的技术平台，它拥有的是一个在学术上合理、在工程上可行、但在IP和临床数据上都尚未建立壁垒的跟随式平台。这与"中国首个"的品牌标签形成了微妙的张力——首个不等于最优，先发卡位在体内CAR-T这种技术快速迭代的赛道，并不必然转化为商业胜势。
第六章 全球市场空间分析6.1 MM全球流行病学与治疗格局
GLOBOCAN 2024估计全球MM新发约19.6万例/年；美国NCI SEER数据现患约17–18万、年新发约3.5万、死亡约1.3万；中国GBD 2021数据2021年新发17,250例、死亡12,984例，中华血液学杂志2024多中心研究估算2025年中国MM现患已突破18万例，中位发病年龄约57岁（比欧美小约5岁）。7MM（美、德、法、意、西、英、日）MM治疗市场2025年约287亿美元，预计以3.3% CAGR增长至2036年——增速远低于CAR-T子赛道，说明传统药物在快速挤压后线治疗价值。6.2 已上市CAR-T销售与市场预测
已上市BCMA CAR-T销售（2025全年实际数）：Carvykti（cilta-cel，传奇/J&J）2025全年净销售额19亿美元，2026Q2单季6.57亿美元（同比+50%），累计治疗超10,000患者，覆盖全球294个中心；Abecma（ide-cel，BMS/2seventy）2024年约5.4亿美元；泽沃基奥仑赛（科济）2024年NMPA获批，2026年进入医保商业化。CAR-T for MM市场预测2025年约48.5亿美元，2032年约206.4亿美元（CAGR 22.98%）。
但天花板正被两类对手同时下压：BCMA×GPRC5D双抗/ADC（teclistamab、elranatamab）把"一次性治愈"叙事拉回到"每季度给药"的慢性模式；Carvykti证明单产品可到20亿美元级别，但这建立在1万患者、294个中心、19.5万美元/疗程定价上。体内CAR-T即便成功，若定价降至5万美元，需治疗4万患者才能达到同等销售——而全球R/R MM后线患者池远小于此。6.3 体内CAR-T的成本优势与冷静的另一面
宣传稿：体外自体CAR-T单批生产成本15–25万美元，体内理论降至1/5–1/10；Carvykti 19.5万美元/疗程，体内若定价5–8万美元，可及性提升3–4倍；无需leukapheresis与2–4周供应链，理论上可在社区医院IV给药。
冷静的另一面：(1) 淋巴清除是否真能省掉？Interius、EsoBiotec、Umoja临床方案仍需flu/cy预处理，否则体内CAR-T无法扩增——若仍需清淋，"社区医院给药"叙事直接破产；(2) LV整合的插入突变风险要求FDA 15年长期随访，真实世界定价优势被大幅侵蚀；(3) VSV-G预存抗体阳性率30–40%，重复给药可能失效。6.4 自免疾病市场与Tempest双平台逻辑
重症肌无力（MG）7MM市场2025年约60亿美元，预计2036年达160亿美元（CAGR 9.1%）；全球MG患者约70–80万。多发性硬化（MS）全球约280万患者，RRMS市场2026年约248亿美元——但MS是CNS疾病，CAR-T进入CNS的安全性数据为零。Tempest叙事是"LNP（瞬时、可重复）+LV（持久、一次给药）双平台分工"：LNP用于自免，LV用于MM。但两个平台需要两套完全不同的CMC体系、监管团队与CDMO供应链，对现金78万美元的公司是战略奢侈。6.5 自免CAR-T的真实竞争格局
CD19 CAR-T在自免领域的热度在2024–2026年快速升温：Carvykti与Abecma已经在MG、系统性红斑狼疮（SLE）、炎性肌病等适应症中显示出ex vivo CAR-T的疗效信号；Sana SC291（CD19异体）GLEAM I期、Capstan CPTX2309（CD8-tLNP）I期健康志愿者、Umoja UB-VV111都在同一条赛道上。Tempest的CD19/BCMA双靶自免设计在科学上合理——CD19覆盖B细胞、BCMA覆盖浆细胞，理论上对MG这种既有B细胞又有自身抗体浆细胞的疾病更彻底——但它并非首创：驯鹿伊基奥仑赛已经在MG中给出I期阳性数据，传奇BRIDGE试验也在推进。森朗通过TPST-4003 IIT获得的中国人体数据，将是这个赛道上的补充证据，而不是定义性证据。6.6 定价与可及性的现实约束
体内CAR-T的经济叙事建立在一个假设上：生产成本从体外的15–25万美元/剂降至1/5–1/10，终端定价从19.5万美元降至5–8万美元。但这个假设忽视了三个现实约束：第一，FDA要求的15年长期随访、RCL检测、生物分布研究、ISA分析，这些监管成本并不会因为"现货型"而消失，反而会因为每个商业化产品都要承担而被摊薄到每剂价格中；第二，体内LV的剂量需求（10¹⁰–10¹¹ vg/剂）意味着载体产能和纯化成本并不像想象中那么低；第三，MM CAR-T已经被双抗（teclistamab、elranatamab）以每季度给药、每针2–3万美元的价格快速挤压，体内CAR-T即便上市，也将面对双抗的定价天花板。Carvykti 19.5万美元/疗程的定价，是建立在"最后线、一次性、10年缓解"的稀缺性上的；如果体内CAR-T把治疗窗口前移到二线、三线，它面对的将是PI、IMiD、CD38单抗、双抗已经把价格压到极低的市场。
第七章 CMC、QA/QC与量产能力分析7.1 森朗CMC家底
据森朗官网，其石家庄高新区基地14,000㎡，2024年5月完成GMP验证，3个独立GMP车间，新商业化基地总投资1.2亿元、设计年产能2,000人份自体CAR-T；工艺为四质粒第三代LV+悬浮无血清包装+三步柱层析。但批判性评估：(1) 悬浮293瞬时转染滴度水平未披露。体内CAR-T所需LV剂量远高于体外：体外转导1患者T细胞约需10⁸–10⁹ TU；体内IV给药按体重通常需10¹⁰–10¹¹ vg/剂（比ex vivo高1–2个数量级）。森朗2,000人份/年自体CAR-T产能能否转化为体内LV批量供应，完全未经验证。(2) 森朗是中国小型biotech，非头部CDMO，缺乏为MNC供临床/商业批次track record。(3) 是否有稳定包装细胞系（可降低RCL风险100倍）未披露——这是尽调必须追问的技术问题。7.2 QA/QC红线：RCL检测
检测项
方法
监管依据
物理滴度vg/mL
qPCR/ddPCR
FDA CMC for Gene Therapy INDs
生物学滴度TU/mL
细胞转导+流式
同上
无菌/支原体/内毒素
USP <71>/<63>/<85>
药典
RCL复制型慢病毒
MT-2/PBMC共培养+qPCR，灵敏度单拷贝
FDA 2006/2020 RCR检测指导原则
宿主细胞蛋白/质粒残留
ELISA/qPCR
CDE指导原则
生物分布/ISA/脱落
体内研究
体内基因治疗新增要求
FDA要求每批载体至少抽检1%批次量或1×10⁸ TU（取较低值）；体内给药因直接入血，监管预期比体外CAR-T更严，受试者长期随访15年。NMPA 2023年《体内基因治疗产品药学研究与评价技术指导原则》已与FDA基本对齐，但生物分布、ISA要求仍参考FDA指南，中国本土长期数据积累不足。7.3 全球LV CDMO产能与tech transfer
主流LV CDMO与交期：Oxford BioMedica（英，Carvykti原CDMO，GMP周期12–18个月，2025年总LV产能超10万升/年）；Charles River（美，12–15个月）；Lonza（8个GMP套件，2026年批次能力180→400/年）；药明生基（较快，但有BIOSECURE风险）；金斯瑞蓬勃/方达/睿智（中国本土）。首次sponsor的LV tech transfer从中国自有GMP转移至OXB/Lonza：RFP签约到首批工艺开发批次6–12个月，工程批+毒理批再加3–6个月，总周期12–18个月、成本约800–1500万美元——这个启动资金本身就超过Tempest全部现金。行权几乎必然伴随新一轮大额融资，或要求森朗承担中国GMP批次供应至海外（又触发人类遗传资源与出口管制问题）。7.4 制造范式转变
FDA将体内LV给药归类为体内基因治疗产品，CMC框架参照2020年终稿《CMC Information for Human Gene Therapy INDs》，而非细胞治疗框架。无需放行细胞活性，但需增加生物分布、载体脱落、ISA、长期LTFU等研究，IND-enabling阶段约增加6–12个月和500–1000万美元成本。范式本质是从"为每个患者定制细胞产品"变为"生产现货型生物制品"，理论规模经济显著——但前提是工艺跑通，而这正是所有体内LV玩家都还在I期剂量爬坡的原因。7.5 供应链地缘政治风险
即使不考虑BIOSECURE Act的直接禁令，从中国向美欧转移体内LV技术还面临多层供应链摩擦。第一，载体生产的地域集中：全球GMP级LV产能高度集中在Oxford BioMedica（英国）、Charles River（美国）、Lonza（瑞士/美国）、Lentigen/Bayer（德国）和少数亚洲CDMO手中，森朗石家庄基地的GMP批次能否被FDA接受用于美国IND，需要完整的CMC等效性研究，周期至少12–18个月。第二，质粒与包装材料：无血清培养基、PEI转染试剂、层析介质、293包装细胞系的关键供应商多在欧美，中国本土替代供应链的GMP合规性尚未经过FDA检查。第三，技术人员跨境流动：tech transfer需要双方CMC团队密切互动，在中美脱钩背景下，森朗核心工艺团队赴美交流的签证与安全审查风险真实存在。第四，临床样本与数据：中国I期产生的患者临床数据、生物样本（PBMC、骨髓、血清）若用于美国BLA，需要满足FDA对外国临床数据的有效性要求（21 CFR 312.120），以及中国人类遗传资源管理条例的出境审批。这些环节任何一个延迟6–12个月，都会显著推迟Tempest行权后的美国IND时间表。7.6 森朗GMP能力的真实成色
森朗官网披露其石家庄基地2024年5月完成GMP验证、3个独立GMP车间、新商业化基地设计年产能2,000人份自体CAR-T。但需要冷静区分"自体CAR-T生产"与"体内LV载体生产"是两种完全不同的制造活动：前者是为每个患者定制的细胞产品，核心质控指标是细胞活性、转导率、残留CD19/CD34、无菌；后者是一个现货型生物制剂，核心质控指标是物理滴度、生物学滴度、RCL、宿主细胞蛋白、质粒残留、内毒素、生物分布。森朗的GMP经验主要沉淀在前者，后者的质控体系（尤其RCL检测、ISA分析、生物分布研究）需要从零建立或依赖外部CDMO。这意味着Tempest行权后，不能简单假设"森朗在中国的GMP能力可以直接平移到美国临床供应"。
第八章 商业秘密防护与跨境合规风险8.1 商密vs专利的策略权衡
体内LV平台中真正难以反向工程的know-how包括：CD7靶向配体氨基酸序列优化与连接子设计、四质粒比例与转染条件（PEI浓度/pH/温度/细胞密度）、纯化工艺参数、制剂配方。这些适合商密保护；而CD7靶向LV核心概念、BCMA/GPRC5D双靶CAR结构、适应症用途容易被规避或反向工程，必须专利化。问题在于：森朗最该专利化的核心平台专利目前在公开数据库中不可见。8.2 跨境授权泄露风险
Tempest行权后必然获得CTD Module 3.2.S技术数据包（工艺规程、SOP、分析方法），这是商密泄露最高危节点。Tempest获得临床批次后可对载体测序和包膜蛋白质谱分析——scFv序列可被还原。因此真正工艺know-how不能写在交付数据包里，而应保留在森朗中国团队手中，以"工艺包持续供应"方式锁定长期价值。8.3 中美商密法律差异与BIOSECURE
中国《反不正当竞争法》第9条与刑法第219条（最高10年有期徒刑）提供刑事保护；美国DTSA（2016）允许联邦管辖与惩罚性赔偿（最高2倍），但DTSA不保护"从中国合法获得的技术数据"——Tempest通过合法tech transfer获得的know-how，森朗在美国难以主张侵权，且美国法院要求"保密措施"达到美国企业标准（分级访问、水印、审计追踪），中国biotech实务胜诉率低。更现实的保护路径是合同条款（数据使用限制、回授、香港/新加坡国际仲裁）。
地缘政治层面：2025年12月BIOSECURE Act被纳入FY2026 NDAA签署成法，禁止美国联邦机构与"Biotechnology Company of Concern"签约或资助；目前被点名的是药明系、华大系等5家，森朗不在清单，但OMB可独立指定。2026年9月3日法院叫停了DoD对药明康德1260H的指定，但OMB路径独立存在。若未来OMB将森朗或其CDMO列为BCC，Tempest可能被迫终止合作，严重影响行权意愿。
更微妙的是，即使森朗本身不在BCC清单上，其CDMO供应商、质粒供应商、甚至合作医院（如北大人民医院、河北医科大学）若有任何一家被纳入观察名单，都可能影响Tempest使用联邦资金推进该资产。Tempest作为纳斯达克上市公司，其未来融资中若出现任何美国政府背景的基金（如California生命科学基金、NCI Small Business Innovation Research资助），都需要在尽调中明确"中国源头资产是否触发BIOSECURE审查"。这一风险在2026年9月的新闻稿中完全未被提及，但它会在Tempest下一轮融资的尽调清单中出现。
人类遗传资源（HGR）层面：2025年4月国家卫健委明确以临床诊疗为目的的CAR-T治疗相关材料出境无需申报HGR材料出境许可——这是利好；但临床数据（尤其基因组数据）出境仍需备案，>500例外显子组/基因组测序数据需安全审查（周期6–12个月）。中国对外汇出技术许可费需经税务备案和外管局登记，预提所得税6–10%（中港安排可降至7%）。此外，中国《技术进出口管理条例》将基因治疗技术列入"限制进出口"目录的可能性，也是森朗与Tempest必须在交易交割前完成法律意见的事项——若技术出口合同未在商务部备案，option fee和里程碑款项将无法合法汇出中国。
第九章 BD价值分析与回款可行性9.1 交易结构：选择权≠正式授权
Tempest获得的是"exclusive option to license"而非直接license：在选择权期内（通常12–24个月），Tempest有权决定是否行权；若不行权，权利回归森朗。选择权期内Tempest通常需承担临床开发费用。新闻稿未披露任何财务条款——option fee金额小到不值得披露本身就是强烈信号。9.2 对标交易对比（明确标注为估算）
交易
类型
Upfront/首付
里程碑/总对价
Royalty
传奇–J&J（2017，Carvykti）
直接授权+合作
$3.5亿
累计已收$2亿，剩余$11.5亿
海外50/50利润分成
Pregene–Kite（2025-10）
直接授权
$1.2亿
$15.2亿
未披露（低双位数）
EsoBiotec–AZ（2025-03）
全资收购
$4.25亿
$5.75亿
N/A
Interius–Kite（2025-08）
全资收购
$3.5亿（全部现金）
N/A
N/A
Kelonia–Lilly（2026-04）
全资收购
$32.5亿
$37.5亿（合计$70亿）
N/A
Capstan–AbbVie（2025-06）
全资收购
约$21亿（总对价）
N/A
森朗–Tempest（2026-09）
独家选择权
未披露（估算$200–800万）
未披露（估算headline $5–15亿，但概率加权后极低）
估算6–10%低双位数
估算逻辑：option-to-license结构下选择权费通常为正式upfront的5–15%；Pregene拿了1.2亿upfront，森朗作为技术路线与Interius高度相似、临床阶段相当但品牌数据更弱的资产，option fee大概率在200万–800万美元；行权价可能3,000万–8,000万美元；headline里程碑5亿–15亿美元；royalty若first-in-class成功上市约低双位数（8–12%），me-too则单位数。9.3 回款可行性：概率加权模型
根据Nature Reviews Drug Discovery 2025与PMC 2025综述，CGT历史转化概率：I→II期约53%、II→III期约48%、III→BLA约46%、BLA→获批约80%，从I期到上市累计约10–15%（肿瘤适应症更低）。对森朗核心资产做概率加权：
图4：BD交易概率加权回款瀑布图（百万美元，估算）
节点
典型金额（估算）
实现概率
概率加权价值
Option费（已签约）
$2–8M
100%
$2–8M（确定性最高）
Tempest行权
$30–80M
30–40%（受现金约束）
$9–32M
II期完成
$30–50M
~20%
$6–10M
III期启动
$50–100M
~10%
$5–10M
BLA提交
$50–100M
~5%
$2.5–5M
首次获批
$100–200M
~3%
$3–6M
商业化里程碑
$100–300M
~1–2%
$1–6M
Royalty（若上市）
销售8–10%
~3%
高度不确定，可能为零
概率加权总回款（NPV粗估）
约$25–70M
历史参照的冷水：生物医药授权交易中公开headline里程碑实际支付率长期低于20%（BIO/Informa历年行业报告），royalty实际产生比例更低——多数license项目在II期前因efficacy/safety失败而终止，royalty永远不会产生。传奇–J&J是极罕见成功案例（Carvykti 2025销售19亿美元），但传奇2017年拿到3.5亿upfront时BCMA CAR-T已有惊艳FIH人体数据。森朗目前公开的体内CAR-T人体数据几乎为零——ASH 2025公布的6项成果均为其体外自体CAR-T（SENL101、SL1703等），而非体内LV资产。这是本次交易最大的估值折让因素。9.4 Tempest执行能力：现金跑道硬约束
Tempest 10-Q：现金从2025年末770.7万美元降至2026-06-30的约78万–122万美元，H1 2026烧钱约1,040万美元，累计赤字2.753亿美元，股东权益-110万美元（资不抵债）。9月11日刚完成250万美元急救式私募。这意味着：(1) Tempest连option fee都可能付得很勉强；(2) 行权几乎必然需新一轮融资或M&A，最可能剧本是Tempest用选择权作为"故事"在未来6–12个月寻求被MNC收购或转授；(3) 团队并无体内CAR-T经验——前身做免疫激活剂TPST-1120（已终止），2026年2月才通过全股票交易获得TPST-2003进入细胞治疗；(4) 若Tempest破产或Nasdaq退市，选择权协议可能成为废纸——森朗必须在协议中保留"若Tempest未按里程碑投入资金，权利自动回归"的reversion条款。9.5 森朗的获益与风险
获益：选择权费现金注入（虽金额不大）；纳斯达克上市背书对中国下一轮融资/IPO有品牌价值；保留中国区权益（中国MM现患18万，若定价50万元/疗程、200单/年即1亿元销售，这是最现实价值锚）；TPST-4003中国IIT由Tempest出钱、森朗出临床执行能力，低成本获得LNP平台中国人体数据。
风险：Tempest行权失败导致技术数据包披露代价无回报；选择权期内Tempest可接触工艺数据后绕开（通过不同scFv序列规避专利）；森朗自身商业化能力未经市场验证——中国已上市CAR-T年销售额均远低于预期，医保谈判后价格大幅下降，保留中国区权益的实际财务价值可能不如headline诱人。9.6 最终判断：BD实际回款可行性
结论：这是一笔"品牌>现金"的战略交易，而非重磅BD。对森朗，选择权费是"定金"不是"货款"，概率加权总回款约2,500万–7,000万美元，且高度依赖未来18个月资本市场环境与Tempest能否融到钱；对Tempest，这是续命稻草而非战略落地。真正的价值兑现要等到行权日——而行权是否发生，不取决于森朗的技术，而取决于Tempest能否融到钱或被MNC收购。9.7 历史数据：milestone实际支付率与royalty实际产生率
生物医药BD行业有一个公开的秘密：新闻稿里的"headline milestone"（总里程碑金额）与实际支付的现金之间，隔着一道巨大的概率鸿沟。BIO与Informa历年行业报告统计，公开披露的license-out交易中，最终实际支付的里程碑总额通常不到headline的20%；而royalty真正产生的比例更低——因为大多数license项目在II期前因efficacy失败、safety信号、竞争格局变化或买方管线调整而终止，royalty窗口从未打开。传奇–J&J之所以成为教科书级成功案例，恰恰因为它是异常值而非中位数：Carvykti从2017年签约到2025年19亿美元销售，用了8年，期间经历了CARTITUDE-1的优异数据、CARTITUDE-4的适应症前移、J&J的全球商业化投入，以及BCMA双抗竞争格局下的定价坚持。森朗目前公开的体内CAR-T人体数据，距离"可被MNC用来做BLA"的成熟度还差至少II期数据读出。
把这一历史规律套到本次交易上：即使headline里程碑真的达到5亿–15亿美元，森朗实际能拿到的现金，按20%支付率折算，也只有1亿–3亿美元区间；再乘以从I期到上市约10–15%的累计概率，NPV粗估就是本文测算的2,500万–7,000万美元。这不是看空森朗，而是生物医药BD的常态。9.8 森朗保留中国区权益的真实价值
森朗保留中国区权益，这是交易结构中最有实际价值的一块。中国MM现患约18万、年新发约2万，若体内CAR-T在中国以50万元人民币/疗程定价、年治疗200例，对应年销售约1亿元人民币；若渗透率提升到500例/年，销售约2.5亿元。但这一测算有三个前提：第一，产品在中国能获批——森朗SENL101尚未上市，SENL103刚获默示许可，其体内LV平台的中国注册路径尚需NMPA IND；第二，医保谈判后价格可能大幅下降——中国已上市CAR-T（阿基仑赛、瑞基奥仑赛、泽沃基奥仑赛、伊基奥仑赛）经医保谈判后定价均从百万级降至数十万级，销量提升但单价腰斩；第三，中国MM后线患者池本身有限——多数MM患者在前线治疗中存活或缓解，真正进入CAR-T后线的年治疗例数全国仅约2,000–3,000例。因此森朗保留中国区权益的财务价值，可能在峰值5亿–10亿元人民币量级，远低于市场对"全球license-out"的想象。9.9 双向选择权的结构性不对称
最后必须点出这笔交易在结构上的不对称性。Tempest获得的是选择权——可以行权、可以放弃、可以拖延；森朗付出的是技术数据包披露——在选择权期内，Tempest及其潜在受让方可以深度接触森朗的工艺、临床前数据、IND材料。如果Tempest最终不行权，森朗付出的披露成本是沉没的；如果Tempest行权，森朗拿到的是一个现金枯竭买方未来可能融到钱的承诺；如果Tempest破产退市，选择权协议可能成为废纸，森朗需要重新寻找买方，而此时技术数据包已经被一个美国上市公司及其顾问看过一遍。这种"买方持有期权、卖方承担披露成本"的不对称结构，在微型Biotech之间的交易中并不罕见，但森朗作为技术输出方，必须在合同中用reversion条款、数据使用限制、反向工程禁止、竞业限制、仲裁地选择（香港/新加坡）等工具，把这种不对称降到可接受水平。
结语：综合判断与建议
对森朗（卖方）：应立即公开——I期试验伦理批件/ChiCTR或NCT注册号、已入组患者数与剂量水平、完整专利清单（含申请号、法律状态、权利要求、同族）、人全血转导率/生物分布/致瘤性/RCL检测临床前数据。应补——核心CD7-LV平台专利的US/EP/JP PCT国家阶段布局；在选择权协议中锁定reversion条款；工艺know-how不出中国，以"持续供应"方式保留；同时与Roche/Novartis/Takeda等MNC保持对话，避免在Tempest一棵树上吊死。
更深一层，森朗需要想清楚自己在这盘棋中的真实位置。过去三年，中国细胞治疗公司出海已经形成了几种范式：传奇–J&J式的"重 upfront+联合开发"，Pregene–Kite式的"大额首付+里程碑"，药明巨诺–BMS式的"绑定MNC全球开发"，以及森朗–Tempest式的"选择权+品牌曝光"。前三种范式背后都有一个共同要素：买方是有足够资金和商业化能力的MNC。Tempest不是MNC，它是一个需要被拯救的壳。森朗选择这种范式，本质上是在"拿不到MNC重磅deal"的前提下，用纳斯达克上市公司的身份为自己的下一轮中国融资背书。这不是错误，但必须清醒认识到：品牌价值是有时效的，若18个月后Tempest退市、选择权作废，"中国首个体内CAR-T出授权"这一标签的含金量会迅速衰减。
对Tempest（买方）：行权决策的关键考量是现金——78万美元连一个美国I期MM试验（成本1,500–3,000万美元）启动都不够，6个月内若不能完成5,000万–1亿美元融资，行权就是空谈；应避免双平台资源分散，聚焦CD7-LV一条路线；行权前必须完成对Interius/Kite CD7-LV专利家族的FTO尽调。
对观察者：应跟踪的里程碑信号包括——ChiCTR/ClinicalTrials.gov是否出现对应注册号；2026 ASH（12月）Kelonia KLN-1010后续数据（直接对标，若强疗效反向验证赛道价值，若安全性事件整个赛道估值回调）；Tempest未来6个月融资进展；选择权是否行权（通常伴随8-K重大协议披露）；森朗是否披露M蛋白下降/MRD阴性率等真正疗效终点。此外，还要关注三个"二阶信号"：第一，Tempest是否在2026Q4完成TPST-4003中国IIT首例给药——若连这一步都跳票，说明双方合作执行力存疑；第二，森朗是否在2026年底–2027年初有PCT专利公开——若此时仍无CD7-LV平台专利公开，IP护城河判断将从"存疑"转为"薄弱"；第三，美国MNC是否在2027年初对森朗直接接触——若Tempest始终融不到钱，森朗很可能绕开Tempest直接与MNC谈判。
风险提示：本文基于截至2026年9月17日公开可获取的一手与二手信源撰写。所有"公司自述"性质陈述均已标注，所有"估算"均明确标注。未被独立信源证实的内容不应作为投资或交易决策唯一依据。本文不构成任何证券买卖建议。TPST为微盘股（市值约1,200万–1,950万美元），存在流动性陷阱、反向拆股与退市风险，专业投资者应等待期权行使、正式license与更多临床数据后再做判断。本文的批判性视角不代表对森朗技术潜力的否定，而是强调：在生物医药这个行业，叙事必须由数据兑现，选择权必须由现金行权，专利必须由公开权利要求支撑——三个"必须"，目前均未被满足。
希望加入“全球GCT行业交流群”的读者，请加以下二维码联系工作人员
信源说明
本文主要引用：Tempest官方GlobeNewswire新闻稿（2026-09-15）；SEC EDGAR 8-K Ex-99.1与2026Q2 10-Q；Lilly收购Kelonia官方新闻稿；Gilead/Kite收购Interius公告；AstraZeneca收购EsoBiotec公告；AbbVie收购Capstan公告；Kite–Pregene交易报道；Legend Biotech与J&J合作及Carvykti财报；Citeline Scrip交易点评；Benzinga/Barchart/雪球行情；ChiCTR2500112124原文；ASCO 2026摘要#260448；Nature Reviews Drug Discovery 2025 CGT成功率综述；PMC体内CAR-T综述（PMC12857126、PMC12962828等）；FDA RCL检测指导原则；DelveInsight/PW Consulting/PharmaDossier市场报告；Morrison Foerster BIOSECURE分析；国家卫健委CAR-T材料出境解答；企查查/水滴信用森朗工商专利信息。所有市场数据与交易金额均以原始公告为准，本文估算部分已在正文逐一标注，不构成任何投资建议。
细胞疗法免疫疗法并购
100 项与 Amezalpat 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性肝细胞癌 | 临床3期 | - | 2025-12-01 | |
| 不可切除的肝细胞癌 | 临床3期 | - | 2025-12-01 | |
| 原发性恶性肝肿瘤 | 临床2期 | 美国 | 2020-11-01 | |
| 原发性恶性肝肿瘤 | 临床2期 | 中国 | 2020-11-01 | |
| 原发性恶性肝肿瘤 | 临床2期 | 法国 | 2020-11-01 | |
| 原发性恶性肝肿瘤 | 临床2期 | 以色列 | 2020-11-01 | |
| 原发性恶性肝肿瘤 | 临床2期 | 新西兰 | 2020-11-01 | |
| 原发性恶性肝肿瘤 | 临床2期 | 韩国 | 2020-11-01 | |
| 原发性恶性肝肿瘤 | 临床2期 | 中国台湾 | 2020-11-01 | |
| 晚期癌症 | 临床1期 | 美国 | 2019-03-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1/2期 | 肝细胞癌 一线 | - | 積遞鑰憲膚憲築繭鹽鹽(淵鏇積簾鹹壓選選鏇鬱) = 鹹鹽糧餘積齋齋遞獵觸 鬱遞製餘積餘構醖憲窪 (觸簾壓衊顧構襯遞願網 ) 更多 | 积极 | 2024-06-20 | ||
積遞鑰憲膚憲築繭鹽鹽(淵鏇積簾鹹壓選選鏇鬱) = 遞繭積壓襯襯願醖衊衊 鬱遞製餘積餘構醖憲窪 (觸簾壓衊顧構襯遞願網 ) 更多 | |||||||
临床1期 | 38 | 糧淵觸齋醖鹽觸窪網蓋(遞蓋糧艱範顧膚蓋淵鑰) = The most common were grade 1-2 nausea, fatigue, and diarrhea. 憲糧積選願願鏇鏇鹹網 (衊餘窪餘艱積艱夢願蓋 ) 更多 | 积极 | 2024-03-29 | |||
临床1/2期 | 70 | 製餘遞願鬱觸夢膚醖製(蓋鏇壓鹽願願網膚築獵) = 繭鑰憲齋鹹廠願醖鑰選 夢淵鹽夢簾鏇遞繭遞鏇 (窪壓簾廠壓艱壓願願鏇 ) 更多 | 积极 | 2023-10-11 | |||
製餘遞願鬱觸夢膚醖製(蓋鏇壓鹽願願網膚築獵) = 觸選積壓膚顧築網壓鏇 夢淵鹽夢簾鏇遞繭遞鏇 (窪壓簾廠壓艱壓願願鏇 ) 更多 | |||||||
临床2期 | 30 | 簾觸窪觸壓願淵簾廠襯(鹹夢構憲鬱網遞選選艱) = 壓遞製廠鬱齋憲製蓋糧 範糧蓋齋鏇獵繭廠齋積 (鹹窪壓蓋築繭鹹夢鑰獵 ) | 积极 | 2022-11-07 | |||
簾觸窪觸壓願淵簾廠襯(鹹夢構憲鬱網遞選選艱) = 膚鑰醖夢築製鹹鑰憲憲 範糧蓋齋鏇獵繭廠齋積 (鹹窪壓蓋築繭鹹夢鑰獵 ) | |||||||
临床1期 | 35 | 齋醖襯廠醖觸繭遞遞築(廠廠淵襯鑰憲醖築壓鑰) = For TPST-1120 monotherapy, the most common treatment related AEs (TRAEs) were nausea (20%), fatigue (15%), and diarrhea (10%), all Grade 1-2. One monotherapy subject (5%) experienced a Grade 3 TRAE (hypertension). In the combination cohort the most common TRAEs related to either drug were fatigue (40%), diarrhea (27%) and nausea (20%), all Grade 1-2. Three combination subjects (19%) experienced Grade 3 TRAEs (one each arthralgia, hepatic enzyme increased, muscle spasms). 憲製鬱鏇獵築願襯顧選 (齋餘廠顧鹽鑰鏇觸選鑰 ) | 积极 | 2022-06-02 | |||
临床1期 | 晚期癌症 FAO/PPARα gene expression | 338 | 壓構願廠壓鬱蓋繭繭鹹(簾醖積鏇廠齋簾壓積醖) = 積衊構範選網願鏇齋廠 窪蓋襯網簾鏇艱築構醖 (壓醖願餘憲醖艱齋觸夢 ) | 积极 | 2019-11-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用